Drug interactions
Ipilimumab + Tisagenlecleucel
Severity: Moderate
Ipilimumab and Tisagenlecleucel: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Ipilimumab activates T cells, and tisagenlecleucel is a CAR-T therapy that can cause cytokine release syndrome, neurotoxicity and prolonged cytopenias. Combining them may intensify immune-mediated toxicity, and no combination data are available.
What this interaction means in plain words
Ipilimumab and Tisagenlecleucel can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Ipilimumab belongs to Oncology; Tisagenlecleucel belongs to Oncology.
Why it happens
Additive immune modulation; checkpoint blockade may enhance CAR-T activation, a largely theoretical interaction.
What to do
Avoid concurrent use around CAR-T infusion unless clearly needed. If used, monitor for cytokine release syndrome, neurotoxicity, immune-related adverse events and infection.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Ipilimumab and Tisagenlecleucel, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Ipilimumab
Other interactions of Tisagenlecleucel
Frequently asked questions
Can I take Ipilimumab with Tisagenlecleucel?
MediHelp rates the interaction as moderate. Ipilimumab and Tisagenlecleucel can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Ipilimumab activates T cells, and tisagenlecleucel is a CAR-T therapy that can cause cytokine release syndrome, neurotoxicity and prolonged cytopenias. Combining them may intensify immune-mediated toxicity, and no combination data are available.
How serious is the interaction between Ipilimumab and Tisagenlecleucel?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid concurrent use around CAR-T infusion unless clearly needed. If used, monitor for cytokine release syndrome, neurotoxicity, immune-related adverse events and infection.
What other medicines interact with Ipilimumab?
MediHelp also lists interactions of Ipilimumab with, for example, Etrasimod, Vemurafenib, Ciltacabtagene autoleucel. The full list is on the Ipilimumab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
